Boston Scientific Reports 2025 Full Year and Q4 Results
Boston Scientific Corporation has reported strong financial results for the fourth quarter and the full year of 2025. The company’s net sales reached $5.286 billion in Q4, marking a significant increase of 15.9% compared to the same period last year. For the entire year, Boston Scientific generated net sales of $20.074 billion, reflecting a growth of 19.9% year-over-year.
Key Financial Highlights
- Q4 2025 Net Sales: $5.286 billion
- Year-End net sales: $20.074 billion
- Q4 GAAP Net Income: $672 million; EPS of $0.45
- Annual GAAP Net Income: $2.898 billion; EPS of $1.94
- Q4 Adjusted EPS: $0.80
- Annual Adjusted EPS: $3.06
Segment Performance
The growth across various segments for the fourth quarter was notable:
- MedSurg: 11.7% reported, 10.2% operational, 6.5% organic growth
- Cardiovascular: 18.2% reported, 16.5% operational, 16.1% organic growth
Geographically, sales growth in Q4 included:
- United States: 17.0% growth
- EMEA: 12.4% growth
- Asia-Pacific: 15.2% growth
- Latin America and Canada: 15.9% growth
Recent Developments
Boston Scientific has made significant advancements in its product offerings and ongoing clinical trials:
- Received FDA approval for the FARAPOINT
Pulsed Field Ablation Catheter. - Initiated enrollment in the OPTIMIZE clinical trial.
- Launched the SEISMIQ Intravascular Lithotripsy System.
Guidance for 2026
The company anticipates continued growth for 2026. Projected net sales growth is estimated at:
- Full Year: 10.5% to 11.5% on a reported basis
- First Quarter: 10.5% to 12.0% on a reported basis
The expected adjusted EPS for the full year ranges from $3.43 to $3.49, whereas for Q1, it is projected between $0.78 to $0.80.
Overall, Boston Scientific’s performance showcases its resilience and capability in the medical technology field, signaling a positive outlook for the future.
